Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [ID6529]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 10 June 2026
Seladelpar for previously treated primary biliary cholangitis [ID6429]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 9 July 2026
Ex-situ machine perfusion devices to preserve deceased donor livers for transplantationStatus:In development | In consultationProgramme:Health technology evaluationConsultation end date: 10 June 2026Expected publication date: 20 August 2026
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)Status:In developmentProgramme:NICE guidelineExpected publication date: 27 July 2027
Maralixibat for treating progressive familial intrahepatic cholestasis [ID3818]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Maralixibat for treating cholestatic pruritus in Alagille syndrome [ID3941]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Semaglutide for treating moderate to advanced liver fibrosis (without cirrhosis) caused by metabolic dysfunction-associated steatohepatitis [ID6458]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Norucholic acid for treating primary sclerosing cholangitis [ID6583]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC